IPO - Heartflow, Inc.

Form Type: S-1

Filing Date: 2025-07-17

Corporate Action: Ipo

Type: New

Accession Number: 000162828025035242

Filing Summary: HeartFlow, Inc. is filing an S-1 registration statement with the U.S. Securities and Exchange Commission for an initial public offering (IPO) of its shares. The company is an emerging growth entity, with its innovative Heartflow Platform designed to provide advanced non-invasive solutions for diagnosing coronary artery disease (CAD) using artificial intelligence and computational fluid dynamics. The Heartflow Platform has been successfully used to assess over 400,000 patients, providing significant insights and improving the accuracy of CAD diagnoses compared to traditional methods. The initial public offering price is expected to be set in a range, contingent upon the company's approval for listing on the Nasdaq under the symbol

Form Type: DRS/A

Filing Date: 2025-06-23

Corporate Action: Ipo

Type: New

Accession Number: 000162827925000389

Filing Summary: Heartflow, Inc. is preparing for an initial public offering (IPO) to sell shares of its common stock, seeking effective registration under the Securities Act of 1933. The offering aims to list on the Nasdaq Global Select Market under the symbol 'HTFL'. The company highlights its use of advanced AI technology for diagnosing coronary artery disease (CAD), asserting that its Heartflow Platform is the most widely adopted test for this condition. The offering is contingent upon SEC approval and will allow significant existing shareholders to maintain substantial control over company decisions. The prospectus outlines key benefits of their technology, expected market size, financial performance, and the competitive edge of their AI-driven assessments, which enhance diagnosis efficiency and precision compared to traditional testing methods. The company has seen recent revenue growth, reporting $125.8 million in revenue for 2024 with a 44% increase from the previous year. The document emphasizes the firm's innovative strategy and readiness for public market entry, targeting a litany of patients suffering from CAD with an estimated market opportunity of around $5 billion.

Form Type: DRS/A

Filing Date: 2025-04-18

Corporate Action: Ipo

Type: New

Accession Number: 000162827925000230

Filing Summary: Heartflow, Inc. has filed a confidential draft registration statement for an initial public offering (IPO) of shares of common stock on April 18, 2025. The company aims to offer shares with an initial public offering price expected to be between an unspecified range. Prior to this offering, there was no public market for the common stock. Heartflow has developed a technology platform that leverages AI for diagnosing and managing coronary artery disease (CAD) and has used its platform to assess over 400,000 patients. Following the offering, executive officers and major stockholders are expected to retain substantial ownership and thereby hold significant control over corporate decisions. The offering is contingent upon approval for listing on the Nasdaq Global Select Market under the symbol 'HTFL'. Heartflow is characterized as an 'emerging growth company' and has outlined its impact in the CAD diagnostics space, including its unique software solutions and past revenue growth. The registration aims to secure funding to further this mission and support future growth initiatives.

Form Type: DRS/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: New

Accession Number: 000162827925000162

Filing Summary: Heartflow, Inc. is initiating its initial public offering (IPO) of common stock with a registration statement filed with the U.S. Securities and Exchange Commission. This prospectus outlines the details for the offering and indicates the company is expected to sell shares at a price range between defined limits per share. The document highlights the Heartflow Platform, which leverages AI for diagnosing and managing coronary artery disease (CAD), and describes its capabilities in providing more accurate assessments of CAD compared to traditional methods. The urgency of the offering is marked by the company's significant market potential, with an estimated opportunity of approximately $5 billion for its Heartflow FFRCT Analysis and similar figures for Heartflow Plaque Analysis. Furthermore, substantial revenue growth has been observed, with a 44% increase year-over-year from the prior year. This IPO aims to support the company’s continued development and expansion within a vital healthcare sector at the forefront of addressing cardiovascular diseases. The company has established its presence as a leading provider of AI-powered diagnostic tools in the medical field, driven by the need for innovative and efficient detection methods in light of the alarming statistics surrounding CAD.

Form Type: DRS

Filing Date: 2025-02-06

Corporate Action: Ipo

Type: New

Accession Number: 000162828025004179

Filing Summary: Heartflow, Inc. filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on February 5, 2025. The draft registration statement under Form S-1 outlines the company's pioneering use of AI and software for non-invasive diagnosis of coronary artery disease (CAD), indicating a significant potential market opportunity in the U.S. of approximately $5 billion. The Heartflow Platform has been utilized to assess CAD in over 375,000 patients, utilizing its advanced technology to generate personalized 3D models from coronary computed tomography angiography (CCTA) scans. The document highlights the clinical effectiveness of the Heartflow Platform, which aims to provide more accurate assessments than traditional non-invasive tests and streamline the patient experience. The company anticipates offering its common stock as part of the IPO, contingent upon receiving necessary approvals. As an emerging growth company, Heartflow is subject to reduced public company reporting requirements and aims to enhance its market presence amidst growing demand for effective CAD diagnostics.